Last reviewed · How we verify
NCT03687905
Proliferative Lupus Nephritis Treatment With Chloroquine and Hydroxychloroquine
trial testing Chloroquine in Proliferative Nephritis in 60 participants. Status unknown.
31 March 2019
Quick facts
| Lead sponsor | Tanta University |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 60 |
| Start date | 18 September 2018 |
| Primary completion | 31 March 2019 |
| Estimated completion | 30 September 2019 |
| Sites | 1 location across Egypt |
Drugs / interventions tested
- Chloroquine (CHLOROQUINE) — full drug profile →
- Hydroxychloroquine (HYDROXYCHLOROQUINE) — full drug profile →
Conditions studied
- Proliferative Nephritis — all drugs for Proliferative Nephritis →
- Chloroquine Retinopathy — all drugs for Chloroquine Retinopathy →
Sponsor
Tanta University
Who can join
Adults 10 to 18, any sex, with Proliferative Nephritis or Chloroquine Retinopathy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Evaluation the efficacy of chloroquine and hydroxychloroquine in the treatment of proliferative lupus nephritis class III and IV in children and adolescents and evaluate the side effects of both drugs .
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Hydroxychloroquine in children with proliferative lupus nephritis: a randomized clinical trial.
Gheet FS, Dawoud HE, El-Shahaby WA, Elrifaey SM, et al · · 2023 · cited 14× · PMID 36752895 · DOI 10.1007/s00431-023-04837-0
Verify or expand the search:
- PubMed search for NCT03687905
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Chloroquine
Trials testing the same drug.
- NCT07352566 — Utilization of a Microdevice for Psoriasis and Atopic Dermatitis · Phase 4 · not yet recruiting
- NCT06666491 — An Interventional Study to Compare the Efficacy and Safety of Tafenoquine (TQ) and Primaquine (PQ) When Either Are Taken · Phase 3 · recruiting
- NCT04704999 — Southeast Asia Dose Optimization of Tafenoquine · Phase 4 · recruiting
- NCT02432417 — The Addition of Chloroquine to Chemoradiation for Glioblastoma, · Phase 2 · withdrawn
- NCT05980156 — Comparing Chemoprevention Drugs for School-based Malaria Control · Phase 4 · completed
Other Tanta University trials
Trials by the same sponsor.
- NCT07398651 — Apremilast and Adalimumab in Psoriatic Arthritis Patients · NA · not yet recruiting
- NCT06966856 — This Randomized, Clinical Trial Evaluates the Efficacy of Oral Versus Sublingual Vitamin B12 Supplementation in Correcti · Phase 3 · not yet recruiting
- NCT07334197 — Effect of Melatonin on Left Ventricular Reverse Remodeling and Inflammation in Peripartum Cardiomyopathy · NA · not yet recruiting
- NCT07498998 — Glucocorticoid, Ozone and 5% Dextrose Local Injection for Pain Relief in Carpal Tunnel Syndrome · NA · not yet recruiting
- NCT07114250 — Comparative Study Between Spinal Anesthesia Versus General Anesthesia in Supine Percutaneous Nephrolithotomy Operation · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03687905 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Tanta University
- Last refreshed: 27 September 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03687905.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing